Author response to: Correspondence to humoral immune response to COVID-19 mRNA vaccine in patients with multiple sclerosis treated with high-efficacy disease-modifying therapies.

Achiron, Anat; Mandel, Mathilda; Dreyer-Alster, Sapir; Harari, Gil; Magalashvili, David; Sonis, Polina; Dolev, Mark; Menascu, Shay; Flechter, Shlomo; Falb, Rina; Gurevich, Michael

Achiron, Anat; Mandel, Mathilda; Dreyer-Alster, Sapir; Harari, Gil; Magalashvili, David; Sonis, Polina; Dolev, Mark; Menascu, Shay; Flechter, Shlomo; Falb, Rina; Gurevich, Michael.

Afiliação

Achiron A; Multiple Sclerosis Center, Sheba Medical Center, 2 Derech Sheba, Ramat-Gann, 52621, Israel.
Mandel M; Multiple Sclerosis Center, Sheba Medical Center, Ramat-Gann, Israel.
Dreyer-Alster S; Multiple Sclerosis Center, Sheba Medical Center, Ramat-Gann, Israel.
Harari G; Multiple Sclerosis Center, Sheba Medical Center, Ramat-Gann, Israel.
Magalashvili D; Multiple Sclerosis Center, Sheba Medical Center, Ramat-Gann, Israel.
Sonis P; Multiple Sclerosis Center, Sheba Medical Center, Ramat-Gann, Israel.
Dolev M; Multiple Sclerosis Center, Sheba Medical Center, Ramat-Gann, Israel.
Menascu S; Multiple Sclerosis Center, Sheba Medical Center, Ramat-Gann, Israel.
Flechter S; Multiple Sclerosis Center, Sheba Medical Center, Ramat-Gann, Israel.
Falb R; Multiple Sclerosis Center, Sheba Medical Center, Ramat-Gann, Israel.
Gurevich M; Multiple Sclerosis Center, Sheba Medical Center, Ramat-Gann, Israel.

Ther Adv Neurol Disord ; 14: 17562864211020082, 2021.

Article em En | MEDLINE | ID: mdl-34104221

Palavras-chave

COVID-19; cladrivine; finfolimod; mRNA vaccine; multiple sclerosis; ocrelizumab

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Bases de dados: MEDLINE Idioma: En Revista: Ther Adv Neurol Disord Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Israel